Viewing Study NCT01360892


Ignite Creation Date: 2025-12-24 @ 3:07 PM
Ignite Modification Date: 2026-01-01 @ 10:47 AM
Study NCT ID: NCT01360892
Status: UNKNOWN
Last Update Posted: 2011-05-26
First Post: 2011-05-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
Sponsor: Kindai University
Organization:

Study Overview

Official Title: Prediction of Incidence of Liver Cancer or PorTal Hypertension in Patients With Viral Hepatitis by Use of Real-time Tissue Elastography
Status: UNKNOWN
Status Verified Date: 2010-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PICTURE
Brief Summary: This is a multi-center cohort study in which the Real-time Tissue Elastography® measurements will predict prospectively the incidence of hepatocellular carcinoma, the incidence and severity of gastroesophageal varices ascites and decompensated cirrhosis in hepatitis B or C patients.
Detailed Description: The aim of this study is to validate the predictive value of Real-time Tissue Elastography® by comparison with serum marker or FibroScan® in chronic hepatitis B or C patients.

Every year and for three years, we performed Real-time Tissue Elastography®, blood sampling, gastrointestinal endoscopy. If in the hospital they can perform FibroScan®, FobroScan® also be performed.

Subjects were also performed ultrasonography (US), computed sonography (CT) or magnetic resonance imaging (MRI) evry four or six months.

The time between the Real-time Tissue Elastography®, blood sampling, gastrointestinal endoscopy and FiroScan® must not exceed four weeks.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: